Product Description
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Implicit Bioscience
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis C, Chronic
Phase 1: Ovarian Cancer|Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CDR0000066900 (5O-98-4) | P1 |
Completed |
Ovarian Cancer |
2000-07-01 |
|
ACTRN12606000505505 | P1 |
Terminated |
Hepatitis C, Chronic |
None |
|
ACTRN12607000418471 | P2 |
Completed |
Hepatitis C, Chronic |
None |